Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Latagliata R, Attolico I, Trawinska MM, Capodanno I, Annunziata M, Elena C, Luciano L, Crugnola M, Bergamaschi M, Bonifacio M, Baratè C, Mauro E, Binotto G, Sgherza N, Aguzzi C, Monteleone B, Sorà F, Caocci G, Luzi D, Mariggiò E, Scaffidi L, Cattaneo D, Gozzini A, Di Veroli A, Abruzzese E, Galimberti S, Iurlo A, Specchia G, Breccia M. Latagliata R, et al. Among authors: barate c. Hematol Oncol. 2021 Aug;39(3):401-408. doi: 10.1002/hon.2851. Epub 2021 Mar 13. Hematol Oncol. 2021. PMID: 33617659
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.
Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Baratè C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F; GIMEMA. Efficace F, et al. Among authors: barate c. Blood. 2011 Oct 27;118(17):4554-60. doi: 10.1182/blood-2011-04-347575. Epub 2011 Jul 12. Blood. 2011. PMID: 21750313 Free article.
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
Defina M, Ippoliti M, Gozzetti A, Abruzzese E, Castagnetti F, Crupi R, Tiribelli M, Breccia M, Salvucci M, Aprile L, Baratè C, Gozzini A, Rosti G, Lauria F, Bocchia M. Defina M, et al. Among authors: barate c. Cancer. 2012 Nov 1;118(21):5265-9. doi: 10.1002/cncr.27506. Epub 2012 Apr 19. Cancer. 2012. PMID: 22517301 Free article.
Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib.
Carulli G, Baratè C, Marini A, Ottaviano V, Cervetti G, Fontanelli G, Guerrini F, Arici R, Guerri V, Di Paolo A, Polillo M, Ferreri MI, Galimberti S, Petrini M. Carulli G, et al. Among authors: barate c. Hematol Oncol. 2015 Dec;33(4):250-2. doi: 10.1002/hon.2156. Epub 2014 Sep 25. Hematol Oncol. 2015. PMID: 25256816 No abstract available.
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients.
Caocci G, Martino B, Greco M, Abruzzese E, Trawinska MM, Lai S, Ragatzu P, Galimberti S, Baratè C, Mulas O, Labate C, Littera R, Carcassi C, Gambacorti Passerini C, La Nasa G. Caocci G, et al. Among authors: barate c. Exp Hematol. 2015 Dec;43(12):1015-1018.e1. doi: 10.1016/j.exphem.2015.08.004. Epub 2015 Aug 22. Exp Hematol. 2015. PMID: 26306453 Free article. Clinical Trial.
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia.
Crea F, Di Paolo A, Liu HH, Polillo M, Clermont PL, Guerrini F, Ciabatti E, Ricci F, Baratè C, Fontanelli G, Barsotti S, Morganti R, Danesi R, Wang Y, Petrini M, Galimberti S, Helgason CD. Crea F, et al. Among authors: barate c. Epigenomics. 2015 Aug;7(5):757-65. doi: 10.2217/epi.15.35. Epub 2015 Sep 7. Epigenomics. 2015. PMID: 26343356 Free PMC article.
76 results